Singapore Clinical Trial: A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the effi... Read More

Singapore Clinical Trial: A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab A... Read More

Singapore Clinical Trial: A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants with Type 2 Diabetes Mellitus and Participants with Overweight or Obesity without Type 2 Diabetes Mellitus.

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Ret... Read More

Singapore Clinical Trial: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination Wi... Read More

Singapore Clinical Trial: EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

Singapore, April 7 -- The Health Sciences Authority received information related to the study titled 'EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate ... Read More

MIB extends TRP freeze on TV news channels by four weeks

India, April 7 -- The Ministry of Information and Broadcasting (MIB) has extended its direction to the Broadcast Audience Research Council (BARC) to withhold television rating points (TRPs) for news c... Read More

CM Pinarayi Vijayan's 'Dash Mone Revanth,' jab at Telangana counterpart's "Nee Po..." on eve of Keralam polls

Kannur, April 7 -- Just ahead of Assembly polls in Keralam, chief minister Pinarayi Vijayan on Tuesday made an acerbic jab at Telangana counterpart and Congress leader Revanth Reddy, borrowing from th... Read More

UN Warns Pregnant Women's Health at Risk in Afghanistan

Afghanistan, April 7 -- The United Nations has warned that ensuring pregnant women in Afghanistan have access to essential health services is critical amid contraceptive restrictions. Pregnant women ... Read More

Quote of the day by Quentin Tarantino: 'Movies are my religion and God is my patron. I'm lucky enough to.'

New Delhi, April 7 -- Quentin Tarantino is one of the most influential filmmakers of modern cinema, known for his bold storytelling, sharp dialogue and distinctive style. With films such as Pulp Ficti... Read More

'Follower of Kisan Andolan': Police on UP man who breached Delhi Assembly security; court grants 8-day custody

India, April 7 -- A Delhi court on Tuesday sent the man who breached the security at the Delhi assembly premises to eight days in police custody. Even as the accused, identified as Sarabjeet Singh, w... Read More

• ««
• «
• 62
• 63
• 64
• 65
• 66
• 67
• 68
• 69
• 70
• 71
• »
• »»